India, July 16 -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, announced the appointment of Christopher Peetz to its Board of Directors, effective from July 15, 2026.
Peetz is co-founder and Chief Executive Officer (CEO) of Mirum Pharmaceuticals Inc. (MIRM), where he has led the company's growth as a rare disease biopharmaceutical firm since its founding in 2018. He also currently serves as entrepreneur-in-residence at Frazier Life Sciences.
Previously, Peetz served as CEO of Flashlight Therapeutics and as Chief Financial Officer (CFO) and Head of Corporate Development at Tobira Therapeutics Inc. (TBRA) prior to its acquisition by Allergan.
googletag.cmd.push(function()...